A Recent Review on Cancer Nanomedicine

SIMPLE SUMMARY: The advancement of nanotechnology over the last three decades has given new hope to cancer management. The first FDA-approved nanomedicine (DOXIL) was made available in the market in 1995. Since then, numerous nanocarriers have been synthesized and extensively evaluated for antitumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Giri, Paras Mani, Banerjee, Anurag, Layek, Buddhadev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136552/
https://www.ncbi.nlm.nih.gov/pubmed/37190185
http://dx.doi.org/10.3390/cancers15082256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136552/
https://www.ncbi.nlm.nih.gov/pubmed/37190185
http://dx.doi.org/10.3390/cancers15082256

Ejemplares similares